USA flag logo/image

An Official Website of the United States Government

Technologies to Defeat Improvised Explosive Devices (IED's)

Award Information

Agency:
Department of Defense
Branch:
Navy
Award ID:
70346
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
N042-901-0443
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NANOTHERAPEUTICS, INC.
13859 Progress Blvd. ALACHUA, FL -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2006
Title: Technologies to Defeat Improvised Explosive Devices (IED's)
Agency / Branch: DOD / NAVY
Contract: N00014-06-C-0043
Award Amount: $940,875.00
 

Abstract:

The overall goal of this Phase II project is to develop the Nanobreathr detection system for proximity detection of explosives at 50 meters, and specifically detection of peroxide improvised explosive devices (IED's) such as TATP and HMTD. Pentagon statistics show that about half the U.S. battle deaths occurred as a result of homemade, easy-to-hide IED's. Proximity vapor sampling and detection is non-invasive and allows wide area detection from stationary or moving air sampling. In the Phase I SBIR project, Nanotherapeutics, Inc. was successful in demonstrating proximity detection of triacetone triperoxide (TATP) peroxide explosive using its proprietary Nanobreathr preconcentrator and 4-SAW array. The current Nanobreathr setup was successfully able to provide sensitive and vapor specific detection proportional to a 100 gram TATP IED 5 to 10 meters away and Phase II studies are proposed to improve the sensitivity and specificity resulting in a device that can provide rapid detection of concealed explosives at safe distances (50 meters). The Phase II project will include development and testing of a robust, commercializable detection system (System modification, IED agent vapor quantification, IED agent challenge, laboratory interference tests, and field interference tests) in collaboration with its commercialization partner RF Monolithics, Inc.

Principal Investigator:

James D. Talton
CEO
3864629663
jtalt@nanotherapeutics.com

Business Contact:

James D. Talton
CEO
3864629663
jtalt@nanotherapeutics.com
Small Business Information at Submission:

NANOTHERAPEUTICS, INC.
12085 Research Dr Ste N Suite N Alachua, FL 32615

EIN/Tax ID: 593615370
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No